Kezar Life Sciences Action: Clinical Study stopped

The Kezar Life Sciences Action has caused a shock, while the Unternehmen are carrying out voluntary patient research and dosing in the phase 2b study PALIZADE. This separation follows the Empfehlung, one of the unreliable dating committees, four of which were a number of serious cases in patients in the Philippine and Argentinian aufgetreten. Kezar appeared to have a problem with the treatment of lung diseases and in früheren clinical trials with zetomipzomib without complications or highly opportunistic infections.

Auswirkungen auf die Aktie

The trade with the Kezar Life Sciences Action was taken into account. This study could have a major impact on the activities of the PALIZADE study, a heavier Meilenstein for the war of the Unternehmen. Investors will increasingly pursue high-risk and low-risk strategies, long-term treatment for zetomipzomib and Kezar’s lung program in the lupus nephritis emerging.

Kezar Life Sciences Promotion: Buy or sell? Read more here…